Shares of Ciphergen Biosystems ( CIPH) jumped Wednesday after it announced an agreement with Quest Diagnostics ( DGX) to co-develop a test for peripheral artery disease.

Ciphergen's shares were gaining 10.1% to 98 cents while Quest's shares were down 1.8% to $52.05.

Under the deal, Quest will assist Ciphergen in the development of the blood-based test. The companies previously agreed to jointly develop a test to detect ovarian tumors.

Peripheral artery disease can lead to clogged blood vessels in the arms and legs which, in severe cases, lead to amputation. Peripheral artery disease affects 8 million to 12 million Americans, according to Ciphergen. Research has shown that nearly 75% of people with the disorder do not experience symptoms.

If you liked this article you might like

Nationwide Egg Recall Expanded

10 Toy Fads That Have Faded

Boomers Feel Recession Burden, Blame

KFC Franchisees Want 'Fried' to Be the Focus

Heavy Weights: More Expensive, Less Effective